Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Wheaton Precious Metals Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while Wheaton Precious Metals Corp trades at $108.3 (market cap $48.84B). The key difference: Wheaton Precious Metals Corp is far larger — about 6.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Wheaton Precious Metals Corp pays a 0.72% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | WPM | |
|---|---|---|
Market Cap | $8.04B | $48.84B |
Sector | Health | Basic Materials |
52-Week High | $339.75 | $165.72 |
52-Week Low | $241.71 | $88.32 |
Enterprise Value | $7.85B | $46.68B |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Wheaton Precious Metals (WPM) trades at $107.83, down 2.02% today, showing bearish technical signals with strong resistance at $108-$110. Fundamentally, the company demonstrates robust performance with Q1 2026 EPS beating expectations at $1.28 versus $1.24, continuing a trend of earnings surprises. Revenue grew to $2.31 billion in 2025 with impressive 65.55% net income margin, though valuation ratios remain elevated with P/E at 27.25.
The stock presents a compelling opportunity with 80% analyst buy ratings and $161.75 consensus price target, representing 50% upside potential. Key risks include precious metal price volatility and the bearish technical outlook. Record cash flow generation and strong production growth support the positive fundamental story despite near-term price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
